APUS
HEALTHCAREApimeds Pharmaceuticals US Inc
$1.95-1.05 (-35.00%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving APUS Today?
No stock-specific AI insight has been generated for APUS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.95$4.03
$1.95
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-0.41
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume806K
Avg Volume (10D)—
Shares Outstanding1.3M
APUS News
13 articles- Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox ProgramYahoo Finance·May 5, 2026
- APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire Inc.·Apr 27, 2026
- Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of ChanceryYahoo Finance·Mar 24, 2026
- Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)Yahoo Finance·Feb 11, 2026
- Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech InnovationYahoo Finance·Nov 10, 2025
- Apimeds Pharmaceuticals says "I love my Ducks" with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of BusinessYahoo Finance·Oct 14, 2025
- Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business DevelopmentYahoo Finance·Sep 15, 2025
- Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain ProgramYahoo Finance·Sep 12, 2025
- Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future LabsYahoo Finance·Aug 25, 2025
- Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² DivisionYahoo Finance·Jul 15, 2025
- D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public OfferingYahoo Finance·May 16, 2025
- Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public OfferingYahoo Finance·May 12, 2025
- Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public OfferingYahoo Finance·May 8, 2025
All 13 articles loaded
Price Data
Open$2.14
Previous Close$3.00
Day High$2.34
Day Low$1.95
52 Week High$4.03
52 Week Low$0.95
52-Week Range
$0.95$4.03
$1.95
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-0.41
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume806K
Avg Volume (10D)—
Shares Outstanding1.3M
About Apimeds Pharmaceuticals US Inc
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—